Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LOX-18228 |
Synonyms | |
Therapy Description |
LOX-18228 is a next-generation RET inhibitor, potentially resulting in decreased cell growth, inhibition of tumor growth, and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1464). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LOX-18228 | LOX 18228|LOX18228 | RET Inhibitor 53 | LOX-18228 is a next-generation RET inhibitor, potentially resulting in decreased cell growth, inhibition of tumor growth, and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1464). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET M918T | Advanced Solid Tumor | predicted - sensitive | LOX-18228 | Preclinical - Cell culture | Actionable | In a preclinical study, LOX-18228 treatment resulted in reduced viability in a cell line expressing RET M918T in culture (Cancer Res 2021;81(13_Suppl):Abstract nr 1464). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|